Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

January 02, 2025

a250102a_00.png

a250102a_01.png

Previous: SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL

Next: LEUPRORELIN EXTENDED-RELEASE INJECTION (SYH9016) OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat